Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2011

01-03-2011

Somatostatin analogs for the treatment of neuroendocrine tumors

Authors: Michael D. Culler, Kjell Öberg, Rudolf Arnold, Eric P. Krenning, Isabel Sevilla, José Ángel Díaz

Published in: Cancer and Metastasis Reviews | Special Issue 1/2011

Login to get access

Abstract

Somatostatin is an important regulator of endocrine and exocrine secretion, affecting the release of many hormones. The effects of somatostatin are mediated through its interaction with one of five somatostatin receptors. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) express multiple somatostatin receptors, making them excellent potential therapeutic targets. Many trials have shown that treatment with somatostatin analogs is associated with disease stabilization and prolonged survival. More recently, somatostatin analogs have been shown to have antiproliferative effects, thus broadening the scope of their uses. In this review, we update the current data on the treatment of GEP-NETs with somatostatin analogs, with particular emphasis on the results of the PROMID study. In addition, we discuss the current state of knowledge of novel therapies against GEP-NETs, including the use of somatostatin analogs with broader receptor binding profiles, chimeric somatostatin–dopamine molecules, combinations of somatostatin analogs with other active chemotherapy agents, and peptide receptor-targeted radionuclide therapy.
Literature
1.
Brazeau, P., Vale, W., Burgus, R., et al. (1973). Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science, 179(68), 77–79.PubMedCrossRef
2.
3.
Serri, O., Brazeau, P., Kachra, Z., et al. (1992). Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: Evidence for a direct and indirect mechanism of action. Endocrinology, 130(4), 1816–1821.PubMedCrossRef
4.
Epelbaum, J. (1986). Somatostatin in the central nervous system: Physiology and pathological modifications. Progress in Neurobiology, 27(1), 63–100.PubMedCrossRef
5.
6.
Bruns, C., Raulf, F., Hoyer, D., et al. (1996). Binding properties of somatostatin receptor subtypes. Metabolism, 45(8 Suppl 1), 17–20.PubMedCrossRef
7.
Hoyer, D., Lubbert, H., & Bruns, C. (1994). Molecular pharmacology of somatostatin receptors. Naunyn Schmiedebergs Arch Pharmacol, 350(5), 441–453.PubMedCrossRef
8.
Oberg, K. E., Reubi, J. C., Kwekkeboom, D. J., et al. (2010). Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology, 139(3), 742–753. 753 e1.PubMedCrossRef
9.
Bauer, W., Briner, U., Doepfner, W., et al. (1982). SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences, 31(11), 1133–1140.PubMedCrossRef
10.
Murphy, W. A., Lance, V. A., Moreau, S., et al. (1987). Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. Life Sciences, 40(26), 2515–2522.PubMedCrossRef
11.
Karashima, T., Cai, R. Z., & Schally, A. V. (1987). Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release. Life Sciences, 41(8), 1011–1019.PubMedCrossRef
12.
Mazziotti, G., Floriani, I., Bonadonna, S., et al. (2009). Effects of somatostatin analogs on glucose homeostasis: A metaanalysis of acromegaly studies. The Journal of Clinical Endocrinology and Metabolism, 94(5), 1500–1508.PubMedCrossRef
13.
Strosberg, J., Gardner, N., & Kvols, L. (2009). Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology, 89(4), 471–476.PubMedCrossRef
14.
Arnold, R., Trautmann, M. E., Creutzfeldt, W., et al. (1996). Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut, 38(3), 430–438.PubMedCrossRef
15.
Saltz, L., Trochanowski, B., Buckley, M., et al. (1993). Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer, 72(1), 244–248.PubMedCrossRef
16.
Ducreux, M., Ruszniewski, P., Chayvialle, J. A., et al. (2000). The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. The American Journal of Gastroenterology, 95(11), 3276–3281.PubMedCrossRef
17.
Wymenga, A. N., Eriksson, B., Salmela, P. I., et al. (1999). Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Journal of Clinical Oncology, 17(4), 1111.PubMed
18.
Susini, C., & Buscail, L. (2006). Rationale for the use of somatostatin analogs as antitumor agents. Annals of Oncology, 17(12), 1733–1742.PubMedCrossRef
19.
Weckbecker, G., Lewis, I., Albert, R., et al. (2003). Opportunities in somatostatin research: Biological, chemical and therapeutic aspects. Nature Reviews. Drug Discovery, 2(12), 999–1017.PubMedCrossRef
20.
Lattuada, D., Casnici, C., Venuto, A., et al. (2002). The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes. Journal of Neuroimmunology, 133(1–2), 211–216.PubMedCrossRef
21.
Florio, T. (2008). Somatostatin/somatostatin receptor signalling: Phosphotyrosine phosphatases. Molecular and Cellular Endocrinology, 286(1–2), 40–48.PubMedCrossRef
22.
Florio, T., Morini, M., Villa, V., et al. (2003). Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology, 144(4), 1574–1584.PubMedCrossRef
23.
Hofland, L. J., & Lamberts, S. W. (2003). The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Reviews, 24(1), 28–47.PubMedCrossRef
24.
Bruns, C., Lewis, I., Briner, U., et al. (2002). SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology, 146(5), 707–716.PubMedCrossRef
25.
Imtiaz, K. E., Monteith, P., & Khaleeli, A. (2000). Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. Clinical Endocrinology (Oxford), 53(6), 755–758.CrossRef
26.
Joensuu, H., Katka, K., & Kujari, H. (1992). Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide. Acta Endocrinologica (Copenhagen), 126(2), 184–185.
27.
Arnold, R., Rinke, A., Klose, K. J., et al. (2005). Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial. Clinical Gastroenterology and Hepatology, 3(8), 761–771.PubMedCrossRef
28.
Faiss, S., Pape, U. F., Bohmig, M., et al. (2003). Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology, 21(14), 2689–2696.PubMedCrossRef
29.
Aparicio, T., Ducreux, M., Baudin, E., et al. (2001). Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. European Journal of Cancer, 37(8), 1014–1019.PubMedCrossRef
30.
di Bartolomeo, M., Bajetta, E., Buzzoni, R., et al. (1996). Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian trials in medical oncology group. Cancer, 77(2), 402–408.PubMedCrossRef
31.
Rinke, A., Müller, H.-H., Schade-Brittinger, C., et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. Journal of Clinical Oncology, 27(28), 4656–4663.PubMedCrossRef
32.
Blumberg J, Gómez-Panzani E, Latapie-Martínez S, et al. Somatuline® Autogel® 120 mg (lanreotide) evaluation of tumor progression-free survival in patients with non-functioning entero-pancreatic endocrine tumors: An ongoing, double-blind, randomized, placebo-controlled, multicenter study (the CLARINET Study). NANETS—2010 Neuroendocrine Tumor Symposium (abstr. 726).
33.
Rocheville, M., Lange, D. C., Kumar, U., et al. (2000). Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science, 288(5463), 154–157.PubMedCrossRef
34.
Schmid, H. A. (2008). Pasireotide (SOM230): Development, mechanism of action and potential applications. Molecular and Cellular Endocrinology, 286(1–2), 69–74.PubMedCrossRef
35.
Van Vugt, H. H., Schmid, H. A., Sailer, A. W. (2008) Ligand-dependent internalization of somatostatin receptors. In: Endocrine abstract. p. 654.
36.
Kvols, L., Wiedenmann, B., Oberg, K., et al. (2006). Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. Journal of Clinical Oncology (Meeting Abstracts), 24(18_suppl), 4082-.
37.
Lamberts, S. W., van der Lely, A. J., de Herder, W. W., et al. (1996). Octreotide. The New England Journal of Medicine, 334(4), 246–254.PubMedCrossRef
38.
Rocheville, M., Lange, D. C., Kumar, U., et al. (2000). Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. The Journal of Biological Chemistry, 275(11), 7862–7869.PubMedCrossRef
39.
Saveanu, A., Gunz, G., Dufour, H., et al. (2001). Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. The Journal of Clinical Endocrinology and Metabolism, 86(1), 140–145.PubMedCrossRef
40.
Minniti, G., Jaffrain-Rea, M. L., Baldelli, R., et al. (1997). Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients. La Clinica Terapeutica, 148(12), 601–607.PubMed
41.
Flogstad, A. K., Halse, J., Grass, P., et al. (1994). A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. The Journal of Clinical Endocrinology and Metabolism, 79(2), 461–465.PubMedCrossRef
42.
Saveanu, A., Lavaque, E., Gunz, G., et al. (2002). Demonstration of enhanced potency of a chimeric somatostatin–dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. The Journal of Clinical Endocrinology and Metabolism, 87(12), 5545–5552.PubMedCrossRef
43.
Kidd, M., Modlin, I. M., Black, J. W., et al. (2007). A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation. Regulatory Peptides, 143(1–3), 109–117.PubMedCrossRef
44.
O’Toole, D., Saveanu, A., Couvelard, A., et al. (2006). The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. European Journal of Endocrinology, 155(6), 849–857.PubMedCrossRef
45.
Hebert, T. E., & Bouvier, M. (1998). Structural and functional aspects of G protein-coupled receptor oligomerization. Biochemistry and Cell Biology, 76(1), 1–11.PubMedCrossRef
46.
Tiensuu Janson, E. M., Ahlstrom, H., Andersson, T., et al. (1992). Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumours. European Journal of Cancer, 28A(10), 1647–1650.PubMedCrossRef
47.
Kolby, L., Persson, G., Franzen, S., et al. (2003). Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. The British Journal of Surgery, 90(6), 687–693.PubMedCrossRef
48.
Terris, B., Scoazec, J. Y., Rubbia, L., et al. (1998). Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology, 32(2), 133–138.PubMedCrossRef
49.
Konno, H., Arai, T., Tanaka, T., et al. (1998). Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm. Japanese Journal of Cancer Research, 89(9), 933–939.PubMed
50.
Yao, J. C., Phan, A., Hoff, P. M., et al. (2008). Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. Journal of Clinical Oncology, 26(8), 1316–1323.PubMedCrossRef
51.
Yuan, R., Kay, A., Berg, W. J., et al. (2009). Targeting tumorigenesis: Development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol, 2, 45.PubMedCrossRef
52.
von Wichert, G., Jehle, P. M., Hoeflich, A., et al. (2000). Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Research, 60(16), 4573–4581.
53.
Moreno, A., Akcakanat, A., Munsell, M. F., et al. (2008). Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocrine-Related Cancer, 15(1), 257–266.PubMedCrossRef
54.
Yao, J. C., Phan, A. T., Chang, D. Z., et al. (2008). Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. Journal of Clinical Oncology, 26(26), 4311–4318.PubMedCrossRef
55.
Yao, J. C., Lombard-Bohas, C., Baudin, E., et al. (2010). Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. Journal of Clinical Oncology, 28(1), 69–76.PubMedCrossRef
56.
Behr, T. M., Memtsoudis, S., Sharkey, R. M., et al. (1998). Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. International Journal of Cancer, 77(5), 787–795.CrossRef
57.
Krenning, E. P., Bakker, W. H., Breeman, W. A., et al. (1989). Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet, 1(8632), 242–244.PubMedCrossRef
58.
Waldherr, C., Pless, M., Maecke, H. R., et al. (2002). Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. Journal of Nuclear Medicine, 43(5), 610–616.PubMed
59.
Appetecchia, M., & Baldelli, R. (2010). Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. Journal of Experimental & Clinical Cancer Research, 29, 19.CrossRef
60.
Heppeler, A., Froidevaux, S., Eberle, A. N., et al. (2000). Receptor targeting for tumor localisation and therapy with radiopeptides. Current Medicinal Chemistry, 7(9), 971–994.PubMed
61.
Reubi, J. C. (2003). Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Reviews, 24(4), 389–427.PubMedCrossRef
62.
Valkema, R., De Jong, M., Bakker, W. H., et al. (2002). Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience. Seminars in Nuclear Medicine, 32(2), 110–122.PubMedCrossRef
63.
Henze, M., Schuhmacher, J., Hipp, P., et al. (2001). PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: First results in patients with meningiomas. Journal of Nuclear Medicine, 42(7), 1053–1056.PubMed
64.
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., et al. (2008). Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: Toxicity, efficacy, and survival. Journal of Clinical Oncology, 26(13), 2124–2130.PubMedCrossRef
65.
Teunissen, J. J., Kwekkeboom, D. J., & Krenning, E. P. (2004). Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. Journal of Clinical Oncology, 22(13), 2724–2729.PubMedCrossRef
66.
van Essen, M., Krenning, E. P., Kam, B. L., et al. (2008). Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 35(4), 743–748.PubMedCrossRef
67.
Arnold, R., Benning, R., Neuhaus, C., et al. (1993). Gastroenteropancreatic endocrine tumours: Effect of Sandostatin® on tumour growth. Digestion, 54(Suppl. 1), 72.PubMedCrossRef
68.
Eriksson, B., Renstrup, J., Imam, H., et al. (1997). High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Annals of Oncology, 8(10), 1041–1044.PubMedCrossRef
69.
Ricci, S., Antonuzzo, A., Galli, L., et al. (2000). Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. American Journal of Clinical Oncology, 23(4), 412–415.PubMedCrossRef
Metadata
Title
Somatostatin analogs for the treatment of neuroendocrine tumors
Authors
Michael D. Culler
Kjell Öberg
Rudolf Arnold
Eric P. Krenning
Isabel Sevilla
José Ángel Díaz
Publication date
01-03-2011
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue Special Issue 1/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-011-9293-0

Other articles of this Special Issue 1/2011

Cancer and Metastasis Reviews 1/2011 Go to the issue

EditorialNotes

Gastroenteropancreatic neuroendocrine tumors. Where are we now?

ReviewPaper

Current knowledge on diagnosis and staging of neuroendocrine tumors

ReviewPaper

Future perspectives on neuroendocrine tumors

ReviewPaper

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

ReviewPaper

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits